Trial Profile
Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing SYR-322 Alone and Combination SYR-322 With Pioglitazone Versus Placebo on Postprandial Lipids in Subjects With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Alogliptin (Primary) ; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Registrational
- Sponsors Takeda
- 12 Jun 2012 Results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
- 26 Apr 2012 New source identified and integrated (EudraCT2007-000486-38: European Clinical Trials Database).
- 12 Jan 2012 Results published in the Diabetologia.